Screener
Rigel Pharmaceuticals RIGL Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Total current liabilities | 89,492 | 99,237 |
| Long-term portion of lease liabilities | 228 | 395 |
| Long-term portion of loans payable, net | 14,991 | 22,482 |
| Total liabilities | 104,711 | 122,114 |
| Commitments | ||
| Stockholders’ equity: | ||
| Common stock | 18 | 18 |
| Additional paid-in capital | 1,414,394 | 1,414,322 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's total liabilities?
- Rigel Pharmaceuticals (RIGL) reported total liabilities of $104.71M in Q1 2026.
- How has Rigel Pharmaceuticals's total liabilities changed year-over-year?
- Rigel Pharmaceuticals's total liabilities decreased by 33.5% year-over-year, from $157.41M to $104.71M.
- What is the long-term trend for Rigel Pharmaceuticals's total liabilities?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's total liabilities has grown at a -2.8% compound annual growth rate (CAGR), from $136.95M to $122.11M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Rigel Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude